CVST is the type of clot that led Germany to halt its rollout of the AstraZeneca vaccine, prompting other countries across Europe to follow. On Thursday, Sweden said it was investigating a new death from CVST in someone who had recently had the vaccine. On Thursday, doctors at the University Hospital of North Norway said they had found evidence that the vaccine was linked to CVST, which killed one Norwegian health worker. But Professor Sir Munir Pirmohamed, the chairman of the Commission on Human Medicines, said the AstraZeneca rollout would continue even if the vaccine was to blame for the rare clotting condition because the benefit would still outweigh the risks. Speaking at Thursday night's Downing Street press conference, Professor Chris Whitty, the chief medical officer, said: "Every medicine, every operation, event vaccination is going to have some risks. "The question is, are the benefits being enough to justify that?